{"id":"neoral-sirolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Gingival hyperplasia"},{"rate":null,"effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination pairs two immunosuppressive agents with complementary mechanisms: cyclosporine inhibits calcineurin-dependent IL-2 production and T-cell activation, while sirolimus (rapamycin) blocks mTOR signaling downstream to prevent cell cycle progression. Together they provide synergistic immunosuppression for transplant rejection prevention and autoimmune conditions.","oneSentence":"Sirolimus inhibits mTOR kinase to suppress T-cell proliferation and immune activation, while Neoral (cyclosporine) blocks calcineurin to prevent T-cell activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:57:06.585Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention (renal, cardiac, hepatic)"},{"name":"Autoimmune and inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06752694","phase":"PHASE2","title":"Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-25","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT07366801","phase":"PHASE2, PHASE3","title":"Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-09-03","conditions":"Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk","enrollment":64},{"nctId":"NCT00133887","phase":"PHASE3","title":"TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2004-04","conditions":"Skin Cancer, Kidney Transplantation","enrollment":77},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT00799188","phase":"PHASE3","title":"CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-10","conditions":"Cardiac Transplantation, Skin Cancer","enrollment":175},{"nctId":"NCT03216967","phase":"PHASE4","title":"Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2018-01-15","conditions":"BK Virus Nephropathy After Kidney Transplantation","enrollment":130},{"nctId":"NCT07173114","phase":"","title":"New Approaches for Evaluating the Interchangeability of Reference Materials and Quality Controls (COMET-MPL)","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09-22","conditions":"Hospitalization, All Conditions","enrollment":300},{"nctId":"NCT00812786","phase":"PHASE4","title":"Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2007-07","conditions":"Heart Transplant","enrollment":42},{"nctId":"NCT04989686","phase":"","title":"Microsampling Assays for Immunosuppressive Drugs in Children","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-06-08","conditions":"Immunosuppression","enrollment":66},{"nctId":"NCT00544115","phase":"PHASE2","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2001-10-16","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":260},{"nctId":"NCT06802055","phase":"PHASE2","title":"Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-01-25","conditions":"Aplastic Anaemia","enrollment":40},{"nctId":"NCT03246906","phase":"PHASE2","title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2017-09-11","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma","enrollment":150},{"nctId":"NCT00866684","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-01-01","conditions":"Skin Cancer","enrollment":44},{"nctId":"NCT06504225","phase":"","title":"EVEROLD LONG TERM FOLLOW-UP","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2024-08-23","conditions":"Transplant; Complication, Failure","enrollment":260},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT06225206","phase":"","title":"Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients","status":"UNKNOWN","sponsor":"Methodist Health System","startDate":"2021-07-01","conditions":"Liver Transplant Failure","enrollment":300},{"nctId":"NCT00518375","phase":"PHASE4","title":"Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-04","conditions":"Kidney Transplantation","enrollment":250},{"nctId":"NCT03871361","phase":"PHASE2","title":"Abatacept in Patients With Birdshot HLA A29 Uveitis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-04-01","conditions":"Eye Diseases, Uveitis","enrollment":15},{"nctId":"NCT04888741","phase":"PHASE2","title":"Methods of T Cell Depletion Trial (MoTD)","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia","enrollment":400},{"nctId":"NCT00681213","phase":"PHASE4","title":"Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation","status":"COMPLETED","sponsor":"University of Miami","startDate":"2000-05","conditions":"Adult Primary Kidney Transplantation","enrollment":150},{"nctId":"NCT01650545","phase":"PHASE1, PHASE2","title":"Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-07","conditions":"Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity","enrollment":21},{"nctId":"NCT04470804","phase":"PHASE4","title":"Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA","status":"COMPLETED","sponsor":"Bing Han","startDate":"2020-07-01","conditions":"Pure Red Cell Aplasia, Acquired","enrollment":56},{"nctId":"NCT01976390","phase":"NA","title":"Comparing Everolimus and Sirolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2013-10-01","conditions":"Renal Failure","enrollment":60},{"nctId":"NCT05274308","phase":"","title":"Stability of Tacrolimus, Cyclosporine A, Everolimus and Sirolimus in Whole Blood Patient Samples","status":"COMPLETED","sponsor":"Thermo Fisher Scientific Oy","startDate":"2022-02-07","conditions":"Transplantation Drugs Stability","enrollment":46},{"nctId":"NCT02329808","phase":"","title":"Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-06","conditions":"Hematologic Diseases, Oncology Problem, Kidney Diseases","enrollment":93},{"nctId":"NCT02756572","phase":"PHASE2","title":"Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-09-22","conditions":"Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm","enrollment":30},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT00061360","phase":"PHASE2","title":"Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2003-06-26","conditions":"Severe Aplastic Anemia","enrollment":77},{"nctId":"NCT04906304","phase":"NA","title":"Comparison of Safety and Efficacy of de Novo Everolimus","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-01-01","conditions":"Cytomegalovirus Infections","enrollment":35},{"nctId":"NCT01936519","phase":"NA","title":"Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-12-16","conditions":"Immunosuppression, Renal Failure","enrollment":24},{"nctId":"NCT01062555","phase":"PHASE1, PHASE2","title":"Calcineurin Inhibitor Sparing After Kidney Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2006-10-01","conditions":"CNI Side Effects","enrollment":527},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT00150046","phase":"PHASE3","title":"Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-12","conditions":"Heart Transplantation","enrollment":176},{"nctId":"NCT01251575","phase":"PHASE2","title":"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-12-01","conditions":"Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma","enrollment":77},{"nctId":"NCT01231412","phase":"PHASE3","title":"Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-11","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma","enrollment":174},{"nctId":"NCT02864706","phase":"PHASE4","title":"SCHEDULE Follow Up Visit 5-7 yr","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-01-18","conditions":"Heart Transplantation","enrollment":95},{"nctId":"NCT01878786","phase":"PHASE2, PHASE3","title":"A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys","status":"TERMINATED","sponsor":"Matthew Cooper","startDate":"2013-06","conditions":"Delayed Graft Function","enrollment":25},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT00520130","phase":"PHASE1, PHASE2","title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-10-30","conditions":"Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease","enrollment":92},{"nctId":"NCT00928018","phase":"PHASE3","title":"Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-06","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":139},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT00074490","phase":"PHASE2","title":"Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-01-01","conditions":"Lymphoma, Leukemia, Myeloproliferative Disorders","enrollment":442},{"nctId":"NCT01601821","phase":"PHASE4","title":"Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-04","conditions":"Inflammation","enrollment":245},{"nctId":"NCT01106833","phase":"PHASE2, PHASE3","title":"Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2010-04","conditions":"Chronic GVHD","enrollment":151},{"nctId":"NCT02328963","phase":"PHASE4","title":"Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-05-02","conditions":"Transplantation Infection, Cytomegalovirus Infection","enrollment":186},{"nctId":"NCT01595984","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2012-05-03","conditions":"Kidney Failure","enrollment":90},{"nctId":"NCT00154284","phase":"PHASE3","title":"Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-07","conditions":"Organ Transplantation, Renal Transplantation","enrollment":114},{"nctId":"NCT00862979","phase":"PHASE4","title":"A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02-24","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT01369082","phase":"","title":"Extended Follow-Up After Islet Transplantation in T1D","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-05","conditions":"Type 1 Diabetes (T1D), Islet Transplantation","enrollment":75},{"nctId":"NCT00923845","phase":"PHASE2","title":"Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-03-01","conditions":"Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome","enrollment":25},{"nctId":"NCT00716573","phase":"PHASE4","title":"Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-09-16","conditions":"Cardiac Transplantation, Chronic Renal Insufficiency","enrollment":120},{"nctId":"NCT00079183","phase":"PHASE2","title":"Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2002-04","conditions":"Graft Versus Host Disease","enrollment":44},{"nctId":"NCT01410448","phase":"PHASE3","title":"Everolimus in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Kidney Transplantation","enrollment":383},{"nctId":"NCT01313923","phase":"EARLY_PHASE1","title":"Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2011-02","conditions":"Pemphigus","enrollment":3},{"nctId":"NCT00043979","phase":"PHASE2","title":"Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-09-19","conditions":"Sarcoma","enrollment":60},{"nctId":"NCT01114529","phase":"PHASE3","title":"Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08-09","conditions":"Kidney Transplantation","enrollment":828},{"nctId":"NCT00513474","phase":"PHASE1","title":"Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-01","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":46},{"nctId":"NCT01797315","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"University Hospital of Berlin","startDate":"2007-03","conditions":"Renal Transplant Patients at High-risk for Skin Cancer","enrollment":40},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00425308","phase":"PHASE3","title":"Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Renal Transplantation","enrollment":30},{"nctId":"NCT00820911","phase":"PHASE2","title":"Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-09","conditions":"Kidney Transplantation","enrollment":175},{"nctId":"NCT00098007","phase":"PHASE3","title":"A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-08-09","conditions":"Heart Transplantation","enrollment":199},{"nctId":"NCT01509560","phase":"PHASE2","title":"PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood","status":"COMPLETED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2011-11-01","conditions":"Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)","enrollment":21},{"nctId":"NCT00514514","phase":"PHASE3","title":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":802},{"nctId":"NCT00834496","phase":"","title":"Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation","status":"WITHDRAWN","sponsor":"Thomas Jefferson University","startDate":"2009-01","conditions":"Side Effects of Calcineurin Inhibitors, Renal Toxicity, Hepatic Fibrosis on Biopsy","enrollment":""},{"nctId":"NCT01492894","phase":"PHASE4","title":"Kidney Allograft Dysfunction Without Reversible Causes","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2008-01","conditions":"Kidney Graft Dysfunction","enrollment":""},{"nctId":"NCT00170794","phase":"PHASE3","title":"Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-09","conditions":"Cardiac Transplantation","enrollment":""},{"nctId":"NCT00504543","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":311},{"nctId":"NCT00170859","phase":"PHASE4","title":"Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-08","conditions":"Heart Transplantation","enrollment":""},{"nctId":"NCT00170885","phase":"PHASE4","title":"Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-05","conditions":"Kidney Transplantation","enrollment":""},{"nctId":"NCT00464399","phase":"PHASE3","title":"Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"De Novo Renal Transplantation","enrollment":20},{"nctId":"NCT00023244","phase":"PHASE2","title":"Steroid Withdrawal in Pediatric Kidney Transplant Recipients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-01","conditions":"End-Stage Renal Disease","enrollment":274},{"nctId":"NCT01023815","phase":"PHASE3","title":"Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-04","conditions":"de Novo Kidney Transplant Recipients, Renal Transplantation","enrollment":330},{"nctId":"NCT01374750","phase":"PHASE2","title":"Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2010-05","conditions":"Hepatocellular Carcinoma","enrollment":45},{"nctId":"NCT02686619","phase":"PHASE3","title":"Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":"Renal Transplantation","enrollment":237},{"nctId":"NCT01046045","phase":"PHASE4","title":"Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2008-04","conditions":"Chronic Allograft Dysfunction in Renal Transplantation","enrollment":17},{"nctId":"NCT01266148","phase":"PHASE4","title":"SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11","conditions":"Renal Function and Chronic Allograft Vasculopathy","enrollment":115},{"nctId":"NCT00803816","phase":"PHASE2","title":"Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A","status":"COMPLETED","sponsor":"Carsten Heinz","startDate":"2007-11","conditions":"Uveitis","enrollment":12},{"nctId":"NCT01561404","phase":"PHASE4","title":"Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise","status":"TERMINATED","sponsor":"Josep M Cruzado","startDate":"2011-09","conditions":"Disorder Related to Renal Transplantation, Exercise, Aerobic, Muscle Strength","enrollment":3},{"nctId":"NCT01678937","phase":"","title":"Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-09","conditions":"Liver Transplant Rejection, Immunosuppression","enrollment":31},{"nctId":"NCT00993343","phase":"PHASE3","title":"Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2007-09","conditions":"Graft-versus-host Disease, Survival","enrollment":215},{"nctId":"NCT01469884","phase":"PHASE4","title":"Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients","status":"COMPLETED","sponsor":"Irmandade Santa Casa de Misericórdia de Porto Alegre","startDate":"2011-11","conditions":"Renal Allograft, Hepatitis C","enrollment":30},{"nctId":"NCT01014234","phase":"PHASE2","title":"Rapamycin and Regulatory T Cells in Kidney Transplantation","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2008-07","conditions":"Kidney Transplantation","enrollment":56},{"nctId":"NCT00002790","phase":"PHASE1, PHASE2","title":"Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"1996-03","conditions":"Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT00378014","phase":"PHASE3","title":"Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-08","conditions":"Liver Transplantation","enrollment":276},{"nctId":"NCT01758107","phase":"PHASE4","title":"Study of Cyclosporine Withdrawal Regimen in Thai Renal Transplant Recipients","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2010-08","conditions":"Renal Transplant","enrollment":30},{"nctId":"NCT01017029","phase":"PHASE4","title":"Everolimus in de Novo Heart Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Cardiac Transplantation","enrollment":182},{"nctId":"NCT02314312","phase":"PHASE3","title":"Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2012-01","conditions":"Transplantation of Kidney, Expanded Criteria Donor, ECD","enrollment":48},{"nctId":"NCT00332839","phase":"PHASE4","title":"Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Renal Transplantation","enrollment":93},{"nctId":"NCT00634920","phase":"PHASE4","title":"Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03","conditions":"Renal Function","enrollment":204},{"nctId":"NCT00355862","phase":"PHASE3","title":"Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2006-01","conditions":"Hepatocellular Carcinoma","enrollment":525},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT01028092","phase":"PHASE3","title":"mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2009-03","conditions":"Renal Transplant","enrollment":327},{"nctId":"NCT00790439","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07","conditions":"Diabetes Mellitus, Type I","enrollment":""},{"nctId":"NCT00956293","phase":"PHASE4","title":"Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Renal Transplantation","enrollment":207}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Neoral/Sirolimus","genericName":"Neoral/Sirolimus","companyName":"University of Miami","companyId":"university-of-miami","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sirolimus inhibits mTOR kinase to suppress T-cell proliferation and immune activation, while Neoral (cyclosporine) blocks calcineurin to prevent T-cell activation. Used for Organ transplant rejection prevention (renal, cardiac, hepatic transplantation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}